Program Overview
This continuing medical education series includes three, 30-minute serialized, educational interviews, designed to bring clinicians up to date on novel therapeutic advances to improve outcomes in patients with tenosynovial giant cell tumor (TGCT). Tenosynovial giant cell tumor is a rare tumor that often leads to severe morbidity or functional limitations. TGCT is categorized into two subtypes, localized and diffuse, where the standard of care for localized is surgical resection, though the diffuse form is often recurrent and difficult-to-treat. In this series, William D. Tap, MD, course chair, will interview top experts in the oncology field, delving into the many factors required to manage their patients with TGCT. Current science, clinical characteristics, and criteria for surgical intervention for patients tenosynovial giant cell tumor will be reviewed. The faculty will analyze the latest clinical trial data for pharmacotherapies to reduce morbidity and preserve function and quality of life in patients with TGCT. Finally, the expert faculty will discuss therapeutic approaches, utilizing the applications of the risk evaluation and mitigation strategy, to maintain liver health for patients with tenosynovial giant cell tumor. Upon completion of this activity, learners will gain further insight into how to better treat their patients with TGCT.
Target Audience
Oncologists, connective tissue oncology specialists, orthopedic physicians, and other healthcare providers involved in the management of patients with tenosynovial giant cell tumor
Learning Objective
- Review the current science and clinical characteristics of TGCT, distinguish localized and diffuse, as well as criteria for surgical intervention
- Evaluate the latest scientific data on the clinical trial data for pharmacotherapies to reduce morbidity and preserve function and quality of life in patients with TGCT
- Discuss therapeutic approaches utilizing the applications of the risk evaluation and mitigation strategy to maintain liver health for patients with TGCT
Modules
- Current Science, Clinical Characteristics, and Criteria for Surgical Intervention for TGCT
- Clinical Trial Update for the Pharmacotherapeutic Treatment of TGCT Patients not Amenable to Improvement with Surgery
- Strategies to Develop Comprehensive Treatment Plans to Improve Outcomes and Manage Liver Health for Patients with TGCT
Chair
William D. Tap, MD
Medical Oncologist
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Faculty
Richard F. Riedel, MD
Associate Professor of Medicine with Tenure
Associate Director, Duke Sarcoma Program
Duke Cancer Institute, Duke University
Durham, NC
Andrew J. Wagner, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Senior Physician, Adult Oncology
Dana-Farber Cancer Institute
Boston, MA
Anthony P. Conley, MD
Associate Professor of Medicine
Department of Sarcoma Medical Oncology
University of Texas MD Anderson Cancer Center
Houston,TX
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| William D. Tap, MD | Consultant/Advisor: Agios Pharmaceuticals, Inc.; AmMax Bio Inc.; Atropos Therapeutics Inc.; Blueprint Medicines; Daiichi Sankyo; Deciphera Pharmaceuticals, Inc.; Eli Lilly and Company; EMD Serono; Mundipharma International; NanoCarrier Co., Ltd.
Grant/Research Support: Bioatla; Blueprint Medicines; Daiichi Sankyo; Deciphera Pharmaceuticals, Inc.; Eli Lilly and Company; Immune Design; Novartis AG; Plexxikon Inc.; TRACON Pharmaceuticals, Inc. |
| Richard F. Riedel, MD | Consultant/Advisor: AadI Bioscience; AROG Pharmaceuticals; Daiichi Sankyo; Eli Lilly and Company; F. Hoffman-La Roche Ltd; GlaxoSmithKline; Ignyta, Inc.; Immnue Design; Karyopharm; NanoCarier Co., Ltd.; Novartis AG; Oncternal Therapeutics; Philogen; Plexxikon Inc.; SpringWorks Therapeutics; TRACON Pharmaceuticals, Inc.
Grant/Research Support: Bayer AG; Blueprint Medicines; Daiichi Sankyo; Deciphera Pharmaceuticals, Inc.; Ignyta, Inc.; NanoCarrier Co., Ltd.; SpringWorks Therapeutics |
| Andrew J. Wagner, MD, PhD | Consultant/Advisor: Daiichi Sankyo; Deciphera Pharmaceuticals, Inc.; Eli Lilly and Company; Epizyme, Inc.; Five Prime Therapeutics, Inc.; NanoCarrier Co., Ltd.
Grant/Research Support: Aadi Bioscience; Daiichi Sankyo; Deciphera Pharmaceuticals, Inc.; Eli Lilly and Company; Five Prime Therapeutics, Inc.; Karyopharm; Plexxikon Inc. |
| Anthony P. Conley, MD | Nothing to disclose |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits TM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Daiichi Sankyo.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Daiichi Sankyo do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
